Press Releases

Jun 2, 2022

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

May 23, 2022

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Apr 27, 2022

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Apr 19, 2022

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

Apr 13, 2022

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Apr 5, 2022

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

Mar 22, 2022

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

Mar 16, 2022

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Feb 22, 2022

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Feb 14, 2022

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA